minocycline Side Effects
Also known as: Minocin, Solodyn
Analysis of 11,257 adverse event reports submitted to the FDA from 2004 to 2025.
Total Reports
11,257
Death-Related
1,508
13.4% of reports
Hospitalizations
3,578
31.8% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 1,508 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| OFF LABEL USE | 576 |
| DRUG INEFFECTIVE | 458 |
| C-REACTIVE PROTEIN INCREASED | 424 |
| PAIN | 423 |
| PNEUMONIA | 419 |
| HYPERTENSION | 412 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 407 |
| INFUSION RELATED REACTION | 404 |
| HYPOAESTHESIA | 403 |
| MATERNAL EXPOSURE DURING PREGNANCY | 403 |
| DRUG INTOLERANCE | 398 |
| HEPATIC ENZYME INCREASED | 397 |
| MOBILITY DECREASED | 394 |
| PEMPHIGUS | 394 |
| INTENTIONAL PRODUCT USE ISSUE | 393 |
| RHEUMATOID ARTHRITIS | 392 |
| ARTHRALGIA | 391 |
| GLOSSODYNIA | 390 |
| PSORIATIC ARTHROPATHY | 387 |
| DRUG HYPERSENSITIVITY | 386 |
Reactions in Hospitalization Reports
Top reactions in 3,578 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| OFF LABEL USE | 701 |
| DRUG INEFFECTIVE | 609 |
| PAIN | 600 |
| NAUSEA | 573 |
| FATIGUE | 520 |
| PNEUMONIA | 511 |
| HEADACHE | 473 |
| JOINT SWELLING | 472 |
| C-REACTIVE PROTEIN INCREASED | 466 |
| RASH | 462 |
| HYPERTENSION | 451 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 448 |
| ARTHRALGIA | 436 |
| DRUG HYPERSENSITIVITY | 435 |
| CONDITION AGGRAVATED | 434 |
| ARTHROPATHY | 432 |
| ABDOMINAL DISCOMFORT | 430 |
| MOBILITY DECREASED | 423 |
| MALAISE | 415 |
| RHEUMATOID ARTHRITIS | 415 |
Nearby — Related Medications
What the FAERS Data Reveals About minocycline Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 11,257 voluntary reports linked to minocycline and its brand equivalents (Minocin, Solodyn), spanning 2004 through 2025. Of those, 1,508 (13.4%) listed death as an outcome and 3,578 (31.8%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 64% were female and 35% male; age distribution skews toward 18-44, with 2,924 reports in that bracket. The single most reported reaction is drug ineffective with 1,908 submissions, followed by off label use and nausea.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.